The Danish medicines agency (lægemiddelstyrelsen) has launched a public consultation and states it intends to withdraw the general (automatic) subsidy for a number of medicines used in cancer treatment.

The agency explains its rationale as follows:

• cancer treatment takes place in hospitals
• medicines used in hospitals, or supplied free of charge to non-admitted patients in continued hospital care (per Danish regions’ list of free-of-charge medicine supply), are not considered relevant for general reimbursement
• general reimbursement is intended for prescription medicines purchased by patients at community pharmacies

The agency notes that some of the medicines are also used outside cancer (e.g., infertility, endometriosis, reduction of the uterine lining before potential surgical removal, and precocious puberty), but it assesses that these uses also generally take place in hospitals.

Comments can be submitted by email, including input on any patient groups receiving these medicines on prescription, by 6 May 2026. Hearing responses will be published on the agency’s website.

Read more at https://laegemiddelstyrelsen.dk/da/nyheder/2026/hoering-vi-revurderer-tilskudsstatus-til-en-raekke-laegemidler-mod-kraeft/

Indlægget Denmark consults on reimbursement status for cancer medicines blev først udgivet på NHTA.